Clinical Biomarkers - A Global and Regional Analysis: Focus on Offering, Clinical Area, Technology, Application, End User, and Region - Analysis and Forecast, 2022-2032

Aug 2022| BIS314B| BIS Research

Report Highlights

Global Clinical Biomarkers Market to Reach $54,294.0 Million by 2032

Market Segmentation:

Segmentation 1: by Offering

  • Product
  • Service

Based on offering, with respect to the overall market share, the service segment held the largest share, i.e., 55.41% of the global clinical biomarkers market in 2021. This trend is expected to continue during the forecast period 2022-2032, with the segment anticipated to hold a 52.88% share in 2032. The high share of the service segment is majorly due to the rising demand for clinical biomarkers services in oncology, the rising number of product launches and approval in recent years, and increasing emphasis on the adoption of clinical biomarkers technologies.

Segmentation 2: by Technology

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Other Technologies

Based on technology, in 2021, global clinical biomarkers market was dominated by next-generation sequencing, with a massive market share of 31.28%. This trend is expected to continue during the forecast period 2022-2032, with the segment anticipated to hold a 34.34% share in 2032. This is primarily due to the growing cancer genomics research.

Segmentation 3: by Application

  • Clinical Diagnostic
  • Translational Research

Based on application, the translational research segment accounted for the largest share in 2021, holding a 53.03% market share. This trend is expected to continue during the forecast period 2022-2032, with the translational research segment expecting to have a 54.11% share of the market in 2032.

Segmentation 4: Clinical Area

  • Cancer Biomarker
  • Cardiac Biomarker
  • Neurological Biomarker
  • Infectious Disease Biomarker
  • Immunological Biomarker
  • Non-Invasive Prenatal Testing
  • Other Clinical Areas

Based on clinical area, the cancer biomarkers segment accounted for the largest share in 2021, holding a 42.04% market share. This trend is expected to continue during the forecast period 2022-2032. Increasing cancer cases across the globe will contribute significantly to the growth of this market.

Segmentation 5: by End User

  • Contract Research Organizations (CROs)
  • Research and Academic Laboratories
  • Biopharmaceutical and Biotech Companies
  • Diagnostic Centers
  • Other End Users

Based on end user, the contract research organizations (CROs) segment accounted for the largest share in 2021, holding a 35.69% market share. This trend is expected to continue during the forecast period 2022-2032.

Segmentation 6: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Rest-of-the-World

The North America region is expected to dominate the global clinical biomarkers market during the forecast period 2022-2032. North America has a high adoption rate of cancer genomics research. Backed by several healthcare companies working in the marketplace, the U.S. has the highest implementation of PCR, NGS, and other technologies.

Recent Developments in the Global Clinical Biomarkers Market

  • Acquisition in 2021: NeoGenomics Laboratories acquired Inivata. With this acquisition, the company strengthened its market position and expanded its footprint in the clinical biomarkers market.
  • Collaboration: In 2022, F. Hoffmann-La Roche Ltd collaborated with Nordic Bioscience to strengthen the development of biomarkers for chronic diseases.
  • Product Approval: In 2020, F. Hoffmann-La Roche Ltd received FDA approval for an assay to detect the HER2 biomarker in breast cancer.

Demand – Drivers and Limitations

Following are the demand drivers for the clinical biomarkers market:

  • Increasing Demand for Clinical Biomarker Products
  • Increasing Key Player Initiatives
  • Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally

The market is expected to face some limitations due to the following challenges:

  • Higher Price of Product/Service Hampering the Expansion in Low-Income countries
  • Complex Regulatory Frameworks Delaying the Approval of New Clinical Biomarkers Tests
  • Lack of Qualified Professionals

How can this report add value to an organization?

Product/Innovation Strategy: Product launches and upgrades in the clinical biomarkers industry are aimed at advancing the overall technologies in the market to ensure efficient detection of various applications such as forensic and paternity identification. Several companies, including Thermo Fisher Scientific Inc. and QIAGEN N.V., were involved in product innovations.

Competitive Strategy: Enterprises led by market juggernauts frequently update their product portfolios with innovative and application-specific products to sustain current market competition. Moreover, a detailed competitive benchmarking of the players operating in the global clinical biomarkers market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.


  • Increasing demand for clinical biomarkers products is anticipated to support the growth of the global clinical biomarkers market during the forecast period 2022-2032.
  • The market is expected to grow at a significant growth rate due to opportunities such as the expansion of biomarker discovery and increased research funding for executing research and development exercises.

Impact of COVID-19

The current global clinical biomarkers market comprises various applications such as translational research and clinical diagnostic. It has been noticed that there has been a reduction in the capacity or shutdowns of laboratories and other research institutions, which has led to reduced usage of various products and services related to research.

The government imposed various restrictions during COVID-19, such as travel bans, quarantines, curfews, business shutdowns, and closures. This led to an increased cost of COVID-19-related services. There have been many issues during the COVID-19 pandemic, such as operational failures, shipping issues, inaccurate demand forecasts, and other production issues.

Furthermore, the health and safety of employees were impacted as COVID-19 reduced the efficacy of employees' work potential. However, the market related to COVID-19 grew during the pandemic as customers were in need of testing services. The implementation of lockdown and travel restrictions amidst the pandemic shook the entire clinical biomarkers industry globally, leading to manufacturing difficulties and delays in clinical trials of biomarkers. The following section represents how the COVID-19 crisis is dismantling drug manufacturing along with the other industry sectors that rely on drug discovery and development, disease risk assessment, and others. The pandemic has impacted the clinical biomarkers market, resulting in fewer sales of the services. Furthermore, the sales of products and services would grow after COVID-19, resulting in better-operating outcomes. However, things have been better after the removal of various restrictions and lockdowns imposed by governments.

Global Clinical Biomarkers Market Industry Overview

In 2021, the global clinical biomarkers market was valued at $21,304.3 million, and it is expected to reach $54,294.0 million by 2032, growing at a CAGR of 8.73% during the forecast period 2022-2032. The growth in the global clinical biomarkers market is expected to be driven by the increasing demand for clinical biomarker products, increasing key player initiatives, and increasing prevalence of infectious diseases and various types of cancer globally.

Market Lifecycle Stage

Clinical biomarkers have been extensively preferred in the field of clinical medicine to offer individualized treatment options to patients. Biomarkers are crucial to the rational development of medical therapeutics and are involved in their use in in-vitro diagnostics purposes, particularly in the fields of chronic disease and nutrition. Companies such as Illumina, Inc., F. Hoffmann-La Roche Ltd Agilent Technologies, Inc., and Myriad Genetics, Inc., in the clinical biomarkers market are launching products, majorly focusing on indications for infectious diseases and cancer types such as breast cancer, ovarian cancer, lung cancer, and cervical cancer. Several companies, such as Thermo Fisher Scientific Inc., QIAGEN N.V., NeoGenomics Laboratories, and CENTOGENE N.V., are collaborating and partnering with the stakeholders to develop and expand technological expertise to offer potential products in the global clinical biomarkers market. Breast cancer is the most frequent tumor growth in women, and its incidence experienced innovation in systematic screening. The increasing incidence of breast cancer has led to an increase in demand for its diagnosis and treatment.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

  • Abbott.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • PerkinElmer Inc.
  • Thermo Fisher Scientific Inc.
  • NeoGenomics Laboratories
  • Charles River Laboratories
  • F. Hoffmann-La Roche Ltd
  • Quest Diagnostics Incorporated
  • Enzo Biochem Inc.
  • Myriad Genetics, Inc.
  • bioMérieux S.A.
  • Arsenal Capital Partners
  • Novogene Co., Ltd.
  • Q2 Solutions
  • Caris Life Sciences
  • Broad Institute
  • Personalis Inc.
  • Azenta Life Sciences
  • Discovery Life Sciences(DLS)
  • BGI
  • Eurofins Scientific
  • Becton, Dickinson and Company

BIS Research is a global B2B market intelligence and advisory firm focusing on those emerging technological trends which are likely to disrupt the dynamics of the market.

With over 150 market research reports published annually, BIS Research focuses on high technology verticals such as 3D Printing, Advanced Materials and Chemicals, Aerospace and Defense, Automotive, Healthcare, Electronics and Semiconductors, Robotics and UAV, and other emerging technologies.

Our in-depth market intelligence reports focus on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.

Similar Reports from BIS Research

Global Clinical Biomarkers Market

  • Date - Mar 2020
  • Code - BIS314A

Key Questions Answered in this Report:

  •     What are the major market drivers, challenges, and opportunities in the global clinical biomarkers market?
  •     What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
  •     What are the key technologies that have been used by leading players ...
BIS Research
Price: $5250

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries

Need a custom data table, graph or complete report? Tell us more.